{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T01:45:59Z","timestamp":1770428759560,"version":"3.49.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP20fk0108453"],"award-info":[{"award-number":["JP20fk0108453"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several factors related to anti-spike(S) IgG antibody titers after mRNA COVID-19 vaccination have been elucidated, but the magnitude of the effects of each factor has not been fully understood. This cross-sectional study assessed anti-S and anti-nucleocapsid (N) antibody titers on 3744 healthy volunteers (median age, 36\u00a0years; IQR, 24\u201349\u00a0years; females, 59.0%) who received two doses of mRNA-1273 or BNT162b2 vaccine and completed a survey questionnaire. Multiple regression was conducted to identify factors associated with antibody titers. All but one participant tested positive for anti-S antibodies (99.97%). The following factors were independently and significantly associated with high antibody titer:\u2009&lt;\u20093\u00a0months from vaccination (ratio of means 4.41); mRNA-1273 vaccine (1.90, vs BNT162b2); anti-N antibody positivity (1.62); age (10\u2019s: 1.50, 20\u2019s: 1.37, 30\u2019s: 1.26, 40\u2019s: 1.16, 50\u2019s: 1.15, vs \u226760\u2019s); female (1.07); immunosuppressive therapy (0.54); current smoking (0.85); and current drinking (0.96). The largest impact on anti-S IgG antibody titers was found in elapsed time after vaccination, followed by vaccine brand, immunosuppressants, previous SARS-CoV-2 infection (anti-N antibody positive), and age. Although the influence of adverse reactions after the vaccine, gender, smoking, and drinking was relatively small, they were independently related factors.<\/jats:p>","DOI":"10.1038\/s41598-022-20747-x","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T12:02:41Z","timestamp":1664452961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers"],"prefix":"10.1038","volume":"12","author":[{"given":"Aya","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Kurisu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Hando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khilola","family":"Saipova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayyora","family":"Akhmedova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanon","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Imada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Razeen Ashraf","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Ouoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bunthen","family":"E","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiya","family":"Yokozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"20747_CR1","unstructured":"World Health Organization WHO. Available at: https:\/\/covid19.who.int \/. Accessed 15 Feb 2022."},{"key":"20747_CR2","unstructured":"Ministry of Health, Labour and Welfare Japan. Available at: https:\/\/covid19.mhlw.go.jp\/. Accessed 15 Feb 2022."},{"key":"20747_CR3","unstructured":"Prime Minister\u2019s Office Japan. Available at: https:\/\/www.kantei.go.jp\/jp\/headline\/kansensho\/vaccine.html. Accessed 15 Feb 2022."},{"key":"20747_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"20747_CR5","unstructured":"Pfizer-BioNTech. Pfizer-BioNTech COVID-19 Vaccine (BNT162, PF-07302048). Vaccines and Related Biological Products Advisory Committee Briefing Document. . Available at: https:\/\/www.fda.gov\/media\/144246\/download."},{"key":"20747_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"20747_CR7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/22221751.2021.1953403","volume":"10","author":"J Favresse","year":"2021","unstructured":"Favresse, J. et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg. Microbes Infect. 10, 1495\u20131498 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"20747_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10081952","volume":"10","author":"A Tretyn","year":"2021","unstructured":"Tretyn, A. et al. Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. Cells 10, 1 (2021).","journal-title":"Cells"},{"key":"20747_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jinf.2021.03.015","volume":"82","author":"RJ Harris","year":"2021","unstructured":"Harris, R. J. et al. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. J. Infect. 82, 162\u2013169 (2021).","journal-title":"J. Infect."},{"key":"20747_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00341-21","volume":"9","author":"SE Wheeler","year":"2021","unstructured":"Wheeler, S. E. et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol. Spectr. 9, e0034121 (2021).","journal-title":"Microbiol. Spectr."},{"key":"20747_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249499","volume":"16","author":"AV Wisnewski","year":"2021","unstructured":"Wisnewski, A. V., Campillo Luna, J. & Redlich, C. A. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS ONE 16, e0249499 (2021).","journal-title":"PLoS ONE"},{"key":"20747_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100208","volume":"10","author":"P Naaber","year":"2021","unstructured":"Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. Lancet Reg. Health Eur. 10, 100208 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"20747_CR13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1515\/cclm-2021-0339","volume":"59","author":"E Danese","year":"2021","unstructured":"Danese, E. et al. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: A three-case series. Clin. Chem. Lab. Med. 59, 1585\u20131591 (2021).","journal-title":"Clin. Chem. Lab. Med."},{"key":"20747_CR14","first-page":"1","volume":"1","author":"SAA Coggins","year":"2021","unstructured":"Coggins, S. A. A. et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. medRxiv 1, 1 (2021).","journal-title":"medRxiv"},{"key":"20747_CR15","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of Two RNA-based covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"20747_CR16","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1093\/cid\/ciab381","volume":"73","author":"L M\u00fcller","year":"2021","unstructured":"M\u00fcller, L. et al. Age-dependent immune response to the Biontech\/Pfizer BNT162b2 Coronavirus disease 2019 vaccination. Clin. Infect. Dis. 73, 2065\u20132072 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"20747_CR17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","volume":"9","author":"Y Lustig","year":"2021","unstructured":"Lustig, Y. et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir. Med. 9, 999\u20131009 (2021).","journal-title":"Lancet Respir. Med."},{"key":"20747_CR18","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1001\/jama.2021.7489","volume":"325","author":"BJ Boyarsky","year":"2021","unstructured":"Boyarsky, B. J. et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325, 2204\u20132206 (2021).","journal-title":"JAMA"},{"key":"20747_CR19","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1111\/ajt.16615","volume":"21","author":"A Grupper","year":"2021","unstructured":"Grupper, A. et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am. J. Transplant 21, 2719\u20132726 (2021).","journal-title":"Am. J. Transplant"},{"key":"20747_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jhep.2021.04.020","volume":"75","author":"L Rabinowich","year":"2021","unstructured":"Rabinowich, L. et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J. Hepatol. 75, 435\u2013438 (2021).","journal-title":"J. Hepatol."},{"key":"20747_CR21","first-page":"1","volume":"1","author":"P Deepak","year":"2021","unstructured":"Deepak, P. et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv 1, 1 (2021).","journal-title":"medRxiv"},{"key":"20747_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.abj1031","volume":"6","author":"H Rincon-Arevalo","year":"2021","unstructured":"Rincon-Arevalo, H. et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. 6, 1 (2021).","journal-title":"Sci. Immunol."},{"key":"20747_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI150175","volume":"131","author":"A Sattler","year":"2021","unstructured":"Sattler, A. et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J. Clin. Invest. 131, 1 (2021).","journal-title":"J. Clin. Invest."},{"key":"20747_CR24","first-page":"1","volume":"1","author":"MW Tenforde","year":"2021","unstructured":"Tenforde, M. W. et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. Clin. Infect. Dis. 1, 1 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"20747_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/jmm.0.001387","volume":"70","author":"K Kontopoulou","year":"2021","unstructured":"Kontopoulou, K. et al. Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: Real-world evidence from Greek healthcare workers. J. Med. Microbiol. 70, 1 (2021).","journal-title":"J. Med. Microbiol."},{"key":"20747_CR26","first-page":"57","volume":"1","author":"TR Olariu","year":"2021","unstructured":"Olariu, T. R., Ursoniu, S., Marincu, I. & Lupu, M. A. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine: A 7-month follow-up study. Medicina 1, 57 (2021).","journal-title":"Medicina"},{"key":"20747_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","volume":"27","author":"JE Ebinger","year":"2021","unstructured":"Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27, 981\u2013984 (2021).","journal-title":"Nat. Med."},{"key":"20747_CR28","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMc2101667","volume":"384","author":"F Krammer","year":"2021","unstructured":"Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372\u20131374 (2021).","journal-title":"N. Engl. J. Med."},{"key":"20747_CR29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X","volume":"397","author":"M Prendecki","year":"2021","unstructured":"Prendecki, M. et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet 397, 1178\u20131181 (2021).","journal-title":"Lancet"},{"key":"20747_CR30","first-page":"1","volume":"1","author":"H Blain","year":"2021","unstructured":"Blain, H. et al. Spike antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose. JAMA 1, 1 (2021).","journal-title":"JAMA"},{"key":"20747_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01162-21","volume":"9","author":"JG Montoya","year":"2021","unstructured":"Montoya, J. G. et al. Differences in IgG antibody responses following BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines. Microbiol. Spectr. 9, e0116221 (2021).","journal-title":"Microbiol. Spectr."},{"key":"20747_CR32","first-page":"1","volume":"1","author":"H Kitagawa","year":"2022","unstructured":"Kitagawa, H. et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J. Infect. Chemother. 1, 1 (2022).","journal-title":"J. Infect. Chemother."},{"key":"20747_CR33","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"20747_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257668","volume":"16","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi, M., Higa, Y., Esaki, A., Nabeshima, Y. & Nakazono, A. Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. PLoS ONE 16, e0257668 (2021).","journal-title":"PLoS ONE"},{"key":"20747_CR35","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.vaccine.2022.02.025","volume":"40","author":"N Tani","year":"2022","unstructured":"Tani, N. et al. Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine. Vaccine 40, 2062\u20132067 (2022).","journal-title":"Vaccine"},{"key":"20747_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.vaccine.2022.01.002","volume":"40","author":"Y Uwamino","year":"2022","unstructured":"Uwamino, Y. et al. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff. Vaccine 40, 1019\u20131025 (2022).","journal-title":"Vaccine"},{"key":"20747_CR37","unstructured":"Ortho Clinical Diagnostics.\u00a0VITROS Anti\u2013SARS-CoV-2 S1 Quant IgG reagent pack. 2021."},{"key":"20747_CR38","unstructured":"World Health Organization WHO. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. 2020, WHO Expert Committee on Biological Standardization. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/ecbs\/bs-2020-2403-sars-cov-2-ab-ik-17-nov-2020_4ef4fdae-e1ce-4ba7-b21a-d725c68b152b.pdf?sfvrsn=662b46ae_8&download=true."},{"key":"20747_CR39","unstructured":"Roche Diagnostics. Available at: https:\/\/diagnostics.roche.com\/jp\/ja\/products\/params\/elecsys-anti-sars-cov-2.html."},{"key":"20747_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644 (2021).","journal-title":"Nature"},{"key":"20747_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.850987","volume":"13","author":"B Keshavarz","year":"2022","unstructured":"Keshavarz, B. et al. Trajectory of IgG to SARS-CoV-2 after vaccination with BNT162b2 or mRNA-1273 in an employee cohort and comparison with natural infection. Front. Immunol. 13, 850987 (2022).","journal-title":"Front. Immunol."},{"key":"20747_CR42","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1001\/jama.2021.15125","volume":"326","author":"D Steensels","year":"2021","unstructured":"Steensels, D., Pierlet, N., Penders, J., Mesotten, D. & Heylen, L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA 326, 1533\u20131535 (2021).","journal-title":"JAMA"},{"key":"20747_CR43","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"20747_CR44","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","volume":"184","author":"RP Payne","year":"2021","unstructured":"Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699\u2013714.e11 (2021).","journal-title":"Cell"},{"key":"20747_CR45","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41590-021-01126-6","volume":"23","author":"VG Hall","year":"2022","unstructured":"Hall, V. G. et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat. Immunol. 23, 380\u2013385 (2022).","journal-title":"Nat. Immunol."},{"key":"20747_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","volume":"41","author":"S Fischinger","year":"2019","unstructured":"Fischinger, S., Boudreau, C. M., Butler, A. L., Streeck, H. & Alter, G. Sex differences in vaccine-induced humoral immunity. Semin. Immunopathol. 41, 239\u2013249 (2019).","journal-title":"Semin. Immunopathol."},{"key":"20747_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/trstmh\/tru167","volume":"109","author":"SL Klein","year":"2015","unstructured":"Klein, S. L., Marriott, I. & Fish, E. N. Sex-based differences in immune function and responses to vaccination. Trans. R Soc. Trop. Med. Hyg. 109, 9\u201315 (2015).","journal-title":"Trans. R Soc. Trop. Med. Hyg."},{"key":"20747_CR48","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","volume":"145","author":"CE Gustafson","year":"2020","unstructured":"Gustafson, C. E., Kim, C., Weyand, C. M. & Goronzy, J. J. Influence of immune aging on vaccine responses. J. Allergy Clin. Immunol. 145, 1309\u20131321 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"20747_CR49","first-page":"1","volume":"1","author":"AY Collier","year":"2021","unstructured":"Collier, A. Y. et al. COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. J. Infect. Dis. 1, 1 (2021).","journal-title":"J. Infect. Dis."},{"key":"20747_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3465","volume":"38","author":"M Watanabe","year":"2022","unstructured":"Watanabe, M. et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab. Res. Rev. 38, e3465 (2022).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"20747_CR51","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.cmi.2021.07.042","volume":"27","author":"T Kageyama","year":"2021","unstructured":"Kageyama, T. et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin. Microbiol. Infect. 27, 1861 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"20747_CR52","first-page":"1","volume":"1","author":"AG L\u2019Huillier","year":"2021","unstructured":"L\u2019Huillier, A. G. et al. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: A prospective longitudinal study. Clin. Microbiol. Infect 1, 1 (2021).","journal-title":"Clin. Microbiol. Infect"},{"key":"20747_CR53","first-page":"371","volume":"1","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 1, 371 (2021).","journal-title":"Science"},{"key":"20747_CR54","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.vaccine.2022.02.052","volume":"40","author":"S Yamamoto","year":"2022","unstructured":"Yamamoto, S. et al. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. Vaccine 40, 1924\u20131927 (2022).","journal-title":"Vaccine"},{"key":"20747_CR55","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","volume":"21","author":"JR Teijaro","year":"2021","unstructured":"Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 21, 195\u2013197 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"20747_CR56","unstructured":"Hiroshima Prefectural Government\u2019s official site. Available at: https:\/\/www.pref.hiroshima.lg.jp\/site\/2019-ncov\/. Accessed 13 Sep 2021."},{"key":"20747_CR57","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/jmv.26326","volume":"93","author":"J He","year":"2021","unstructured":"He, J., Guo, Y., Mao, R. & Zhang, J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. J. Med. Virol. 93, 820\u2013830 (2021).","journal-title":"J. Med. Virol."},{"key":"20747_CR58","unstructured":"National institution of infectious diseases Japan. National Institute of Infectious Diseases. Field Briefing: diamond Princess COVID-19 cases (2020)."},{"key":"20747_CR59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijid.2020.03.020","volume":"94","author":"H Nishiura","year":"2020","unstructured":"Nishiura, H. et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int. J. Infect. Dis. 94, 154\u2013155 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"20747_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1265\/ehpm.22-00016","volume":"27","author":"A Sugiyama","year":"2022","unstructured":"Sugiyama, A. et al. A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020. Environ. Health Prev. Med. 27, 30 (2022).","journal-title":"Environ. Health Prev. Med."},{"key":"20747_CR61","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1126\/science.abd7728","volume":"370","author":"A Wajnberg","year":"2020","unstructured":"Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227\u20131230 (2020).","journal-title":"Science"},{"key":"20747_CR62","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 5, 1598\u20131607 (2020).","journal-title":"Nat. Microbiol."}],"updated-by":[{"DOI":"10.1038\/s41598-023-28884-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20747-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20747-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20747-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T12:07:12Z","timestamp":1675512432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20747-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20747"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20747-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-023-28884-7","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-023-28884-7","URL":"https:\/\/doi.org\/10.1038\/s41598-023-28884-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Measurement of antibody by using reagents of Ortho Clinical Diagnostics was technically supported by Ortho Clinical Diagnostics. Professor Junko Tanaka received speaker\u2019s fees from Ortho Clinical Diagnostics. The other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16294"}}